299. Cystic fibrosis Clinical trials / Disease details
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01576315 (ClinicalTrials.gov) | June 2014 | 29/3/2012 | ATCF (Azole Therapy in Cystic Fibrosis) | Efficacy of Itraconazole and of Voriconazole in Patients With Cystic Fibrosis and Presenting With Persistent Positive Sputums for Aspergillus. | Cystic Fibrosis;Aspergillus Infections | Drug: Itraconazole/voriconazole | Rennes University Hospital | NULL | Completed | 12 Years | N/A | Both | 11 | Phase 2 | France;United Kingdom |
| 2 | NCT01768663 (ClinicalTrials.gov) | January 2013 | 11/1/2013 | A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects | A Phase 1, Open-Label Study to Examine the Effect of Ciprofloxacin, Itraconazole, and Rifampin on the Pharmacokinetics of Lumacaftor in Combination With Ivacaftor in Healthy Adult Subjects | Cystic Fibrosis | Drug: Lumacaftor;Drug: Ivacaftor;Drug: Ciprofloxacin;Drug: Itraconazole;Drug: Rifampin | Vertex Pharmaceuticals Incorporated | NULL | Completed | 18 Years | 55 Years | Both | 80 | Phase 1 | United States |
| 3 | EUCTR2011-005799-41-GB (EUCTR) | 04/10/2012 | 21/08/2012 | Azole Therapy in Cystic Fibrosis (ATCF) | Azole Therapy in Cystic Fibrosis (ATCF) : Efficacy of itraconazole and ofvoriconazole in patients with cystic fibrosis and presenting withpersistent positive sputums for Aspergillus - Azole Therapy in Cystic Fibrosis (ATCF) | Cystic fibrosis MedDRA version: 14.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 14.1;Level: HLT;Classification code 10003486;Term: Aspergillus infections;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01] | Trade Name: SPORANOX Product Name: Sporanox 10 mg/ml Oral Solution INN or Proposed INN: ITRACONAZOLE Other descriptive name: SPORANOX Trade Name: V-Fend Product Name: VFEND 40 mg/ml powder for oral suspension INN or Proposed INN: voriconazole Other descriptive name: Vfend | CHU de Rennes (Rennes University Hospital Centre) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | United Kingdom | |||
| 4 | NCT00787917 (ClinicalTrials.gov) | November 2008 | 7/11/2008 | An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) | An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multiple Doses of Omalizumab in Cystic Fibrosis Complicated by Allergic Bronchopulmonary Aspergillosis (ABPA) | Cystic Fibrosis;Allergic Bronchopulmonary Aspergillosis | Drug: Omalizumab;Drug: Placebo;Drug: Itraconazole | Novartis Pharmaceuticals | NULL | Terminated | 12 Years | N/A | All | 14 | Phase 4 | Belgium;Germany;Italy;Netherlands;United Kingdom |
| 5 | NCT00528190 (ClinicalTrials.gov) | October 2007 | 10/9/2007 | Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis | Treatment of Aspergillus Fumigatus in Patients With Cystic Fibrosis: A Randomized, Double-blind, Placebo-Controlled Trial | Cystic Fibrosis | Drug: Itraconazole | Ottawa Hospital Research Institute | The Hospital for Sick Children;Canadian Cystic Fibrosis Foundation;The Physicians' Services Incorporated Foundation | Completed | 6 Years | N/A | All | 35 | Phase 4 | Canada |